
Addus HomeCare (ADUS) Stock Forecast & Price Target
Addus HomeCare (ADUS) Analyst Ratings
Bulls say
Addus HomeCare Corp has demonstrated impressive organic revenue growth post-pandemic, achieving a year-over-year increase of 12.3% in 2023, with sustained growth projections of 7.7% for 2024 and 7.4% year-to-date in 2025. The finalized increase of 2.6% in the Medicare Hospice rate for FY2026 presents a favorable regulatory environment that is likely to enhance revenue streams across its Hospice segment. Additionally, anticipated mergers and acquisitions (M&A) activity, combined with improvements from recent leadership changes, may further bolster operational efficiencies and revenue growth prospects.
Bears say
Addus HomeCare is facing challenges due to ongoing declines in same-store performance, attributed to Medicaid redeterminations that have created administrative bottlenecks, resulting in higher patient discharges relative to admissions. Approximately 97% of the company's segment revenues are affected by the current uncertainty surrounding the future Medicaid funding environment, exacerbated by the implications of the One Big Beautiful Bill Act (OBBBA). Despite its steady operational execution and favorable long-term demand outlook, the company's stock valuation appears disconnected from underlying earnings trajectory, leading to a negative outlook.
This aggregate rating is based on analysts' research of Addus HomeCare and is not a guaranteed prediction by Public.com or investment advice.
Addus HomeCare (ADUS) Analyst Forecast & Price Prediction
Start investing in Addus HomeCare (ADUS)
Order type
Buy in
Order amount
Est. shares
0 shares